See more : Stanmore Resources Limited (STMRF) Income Statement Analysis – Financial Results
Complete financial analysis of OliX Pharmaceuticals,Inc (226950.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OliX Pharmaceuticals,Inc, a leading company in the Biotechnology industry within the Healthcare sector.
- Shell plc (RYDAF) Income Statement Analysis – Financial Results
- Komatsu Wall Industry Co., Ltd. (7949.T) Income Statement Analysis – Financial Results
- Class 1 Nickel and Technologies Limited (NICO.CN) Income Statement Analysis – Financial Results
- MOGAN ENERJI (MOGAN.IS) Income Statement Analysis – Financial Results
- Playgon Games Inc. (PLGNF) Income Statement Analysis – Financial Results
OliX Pharmaceuticals,Inc (226950.KQ)
About OliX Pharmaceuticals,Inc
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.06B | 9.32B | 3.67B | 2.47B | 1.13B | 302.00M | 243.97M | 391.90M | 907.62M |
| Cost of Revenue | 2.64B | 1.97B | 8.36B | 1.39B | 1.06B | 3.88B | 982.70M | 136.56M | 0.00 |
| Gross Profit | 14.42B | 7.35B | -4.68B | 1.09B | 66.53M | -3.58B | -738.73M | 255.34M | 907.62M |
| Gross Profit Ratio | 84.52% | 78.83% | -127.43% | 44.01% | 5.89% | -1,185.79% | -302.80% | 65.15% | 100.00% |
| Research & Development | 18.48B | 16.51B | 14.23B | 9.48B | 8.97B | 2.88B | 3.13B | 2.02B | 1.65B |
| General & Administrative | 1.02B | 862.17M | 1.06B | 1.27B | 175.39M | 104.24M | 83.70M | 0.00 | 0.00 |
| Selling & Marketing | 2.67B | 2.03B | 1.81B | 1.68B | 1.46B | 970.11M | 768.32M | 0.00 | 0.00 |
| SG&A | 14.34B | 12.55B | 4.92B | 7.54B | 6.00B | 1.68B | 1.48B | 2.01B | 1.38B |
| Other Expenses | 0.00 | -657.94M | -395.85M | -310.70M | -211.29M | -175.75M | -57.65M | -44.35M | 0.00 |
| Operating Expenses | 32.66B | 29.72B | 19.55B | 17.33B | 15.18B | 4.74B | 4.67B | 4.08B | 3.03B |
| Cost & Expenses | 35.25B | 31.70B | 27.90B | 18.72B | 16.25B | 8.54B | 5.65B | 4.21B | 3.09B |
| Interest Income | 1.27B | 1.39B | 473.69M | 247.84M | 455.81M | 360.71M | 4.77M | 76.44M | 219.44M |
| Interest Expense | 3.49B | 2.93B | 2.43B | 239.07M | 5.61M | 4.70M | 42.49M | 14.40M | 1.03B |
| Depreciation & Amortization | 2.64B | 1.97B | 1.62B | 1.19B | 775.52M | 508.12M | 369.58M | 136.56M | 55.41M |
| EBITDA | -11.14B | -24.20B | -25.95B | -19.08B | -13.46B | -7.20B | -4.75B | -3.51B | -1.90B |
| EBITDA Ratio | -65.25% | -218.91% | -615.43% | -608.24% | -1,268.77% | -2,587.31% | -2,066.04% | -940.34% | -233.81% |
| Operating Income | -18.19B | -22.38B | -24.23B | -16.24B | -15.12B | -8.32B | -5.41B | -3.82B | -2.18B |
| Operating Income Ratio | -106.57% | -240.07% | -659.40% | -656.41% | -1,337.38% | -2,755.56% | -2,217.53% | -975.19% | -239.91% |
| Total Other Income/Expenses | 15.72M | -6.73B | -5.77B | -4.27B | 873.25M | 491.92M | 22.59M | 166.16M | -804.00M |
| Income Before Tax | -18.17B | -29.11B | -30.00B | -20.51B | -14.24B | -7.74B | -5.16B | -3.66B | -2.98B |
| Income Before Tax Ratio | -106.48% | -312.30% | -816.40% | -828.97% | -1,260.13% | -2,563.58% | -2,116.65% | -932.79% | -328.50% |
| Income Tax Expense | 932.07M | -994.90M | -821.54M | -1.13B | 109.19M | 507.96M | 0.00 | 0.00 | -219.44M |
| Net Income | -19.10B | -19.50B | -29.71B | -19.38B | -14.35B | -7.74B | -5.16B | -3.66B | -2.98B |
| Net Income Ratio | -111.94% | -209.17% | -808.70% | -783.44% | -1,269.79% | -2,563.58% | -2,116.65% | -932.79% | -328.50% |
| EPS | -1.32K | -1.42K | -2.17K | -1.47K | -1.10K | -667.47 | -401.34 | -284.11 | -231.72 |
| EPS Diluted | -1.32K | -1.42K | -2.17K | -1.47K | -1.10K | -667.47 | -401.34 | -284.11 | -231.72 |
| Weighted Avg Shares Out | 14.43M | 13.70M | 13.69M | 13.15M | 13.02M | 11.60M | 12.87M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 14.43M | 13.70M | 13.69M | 13.15M | 13.02M | 11.60M | 12.87M | 12.87M | 12.87M |
Source: https://incomestatements.info
Category: Stock Reports